BrightGene Bio Medical Technology C (688166) — Financial Flexibility Index
BrightGene Bio Medical Technology C (688166) has a Financial Flexibility Index of 0.04x as of June 2023. Free cash flow of CN¥94.76 Million (operating CF CN¥26.70 Million minus capex CN¥68.06 Million) represents 0% of total liabilities (CN¥2.46 Billion). Check strategic asset allocation of BrightGene Bio Medical Technology C to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
BrightGene Bio Medical Technology C Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for BrightGene Bio Medical Technology C across 9 annual periods. See how liquid is BrightGene Bio Medical Technology C's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for BrightGene Bio Medical Technology C (2016–2024)
Year-by-year free cash flow to debt coverage for BrightGene Bio Medical Technology C. For the full company profile including market capitalisation, see 688166 market cap.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.18x | CN¥502.76 Million | CN¥245.56 Million | CN¥2.73 Billion | ▼ -17.5% |
| 2023 | 0.22x | CN¥584.10 Million | CN¥194.77 Million | CN¥2.61 Billion | ▼ -47.9% |
| 2022 | 0.43x | CN¥1.04 Billion | CN¥311.26 Million | CN¥2.42 Billion | ▼ -51.5% |
| 2021 | 0.88x | CN¥1.09 Billion | CN¥176.08 Million | CN¥1.23 Billion | ▼ -31.6% |
| 2020 | 1.29x | CN¥510.70 Million | CN¥155.43 Million | CN¥395.23 Million | ▼ -7.3% |
| 2019 | 1.39x | CN¥150.87 Million | CN¥61.33 Million | CN¥108.21 Million | ▼ -16.6% |
| 2018 | 1.67x | CN¥176.46 Million | CN¥63.99 Million | CN¥105.52 Million | ▲ +10.4% |
| 2017 | 1.51x | CN¥119.47 Million | CN¥35.77 Million | CN¥78.89 Million | ▲ +274.6% |
| 2016 | 0.40x | CN¥66.31 Million | CN¥29.73 Million | CN¥164.05 Million | — |